Media Articles Related to Prolia (Denosumab)
Patients With Osteoporosis Can Live Long Lives
Source: Medscape Diabetes & Endocrinology Headlines [2015.04.24]
Women younger than 75 years and men younger than 60 years can expect to live at least 15 more years after beginning treatment for osteoporosis, according to a new observational study.
Medscape Medical News
Osteoporosis Pictures Slideshow: Super Foods for Your Bones
Source: MedicineNet Exercise and Activity Specialty [2015.04.24]
Title: Osteoporosis Pictures Slideshow: Super Foods for Your Bones
Created: 2/3/2009 12:00:00 AM
Last Editorial Review: 4/24/2015 12:00:00 AM
What's the life expectancy of patients when they begin treatment for osteoporosis?
Source: Bones / Orthopedics News From Medical News Today [2015.04.23]
Despite reports that people with osteoporosis have an increased risk of dying prematurely, a new study has found that life expectancy of newly diagnosed and treated osteoporosis patients is in excess...
Osteoporosis Predisposes to Higher Risk of Sudden Deafness
Source: Medscape Diabetes & Endocrinology Headlines [2015.04.22]
Osteoporosis is associated with a higher risk of sudden sensorineural hearing loss, according to a large epidemiological study from Taiwan. The effect appears amplified with age and female gender.
Medscape Medical News
Osteoporosis diagnosis contributes to hearing loss risk
Source: Bones / Orthopedics News From Medical News Today [2015.04.21]
People who have osteoporosis face a 1.76-fold higher risk of developing sudden deafness than those who do not have the bone disease, according to a new study published in the Endocrine Society's...
Published Studies Related to Prolia (Denosumab)
Clinical Trials Express: fracture risk reduction with denosumab in Japanese
postmenopausal women and men with osteoporosis: denosumab fracture intervention
randomized placebo controlled trial (DIRECT). 
with osteoporosis compared with placebo... CONCLUSION: These results provide evidence of the efficacy and safety of
Delaying skeletal-related events in a randomized phase 3 study of denosumab
versus zoledronic acid in patients with advanced cancer: an analysis of data from
patients with solid tumors. 
myeloma... CONCLUSIONS: Denosumab was more effective in delaying or preventing SREs in
Superiority of denosumab to zoledronic acid for prevention of skeletal-related
events: a combined analysis of 3 pivotal, randomised, phase 3 trials. 
across three pivotal studies... CONCLUSION: Denosumab was superior to zoledronic acid in preventing SRE with
Responder analysis of the effects of denosumab on bone mineral density in men
receiving androgen deprivation therapy for prostate cancer. 
(lumbar spine (LS), femoral neck (FN) and total hip (TH)) and the distal radius... CONCLUSIONS: In men with prostate cancer receiving ADT, significantly higher BMD
Dose-response study of denosumab on bone mineral density and bone turnover
markers in Japanese postmenopausal women with osteoporosis. 
12 months in Japanese postmenopausal women with osteoporosis... CONCLUSIONS: Denosumab 60 mg could be an effective dose for Japanese
Clinical Trials Related to Prolia (Denosumab)
Treatment of Atraumatic Bone Marrow Edema With Denosumab and Teriparatide vs Placebo [Recruiting]
The etiology of bone marrow edema (BME) is still uncertain. Several studies report
therapeutic success with antiresorptive drugs.
This study investigates antiresorptive and osteoanabolic drugs versus placebo in BME
Denosumab for Prevention of Osteoporosis in Renal Transplant Recipients [Recruiting]
The primary objective of the study is to examine the effect of denosumab on total hip bone
mineral density (BMD) after one year of treatment in newly transplanted renal allograft
recipients. Secondary endpoints include BMD changes at the lumbar spine and the femoral
neck, changes in body height, changes in bone mineral metabolism parameters, incidence of
fractures, and allograft function at one year. Safety measurements include the occurrence of
rejection episodes, infectious complications, graft loss and mortality.
- Trial with medicinal product
Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis - The ADAMO Trial [Recruiting]
The purpose of this study is to assess how effective and safe denosumab is in a population
of males with low bone mass at risk of fracture. The primary clinical hypothesis is that in
men with low bone mineral density, the mean percent change in lumbar spine bone mineral
density at 12 months in subjects receiving denosumab will be greater than in subjects
receiving placebo. Denosumab is a fully human monoclonal antibody with a high affinity for
Receptor Activator of Nuclear Factor-kB (RANK) Ligand that can bind and neutralize the
activity of human RANK Ligand similar to the action of endogenous osteoprotegerin.
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium [Recruiting]
The purpose of this study is to determine the potential of denosumab to treat Hypercalcemia
of Malignancy in patients with elevated serum calcium who do not respond to recent treatment
with intravenous bisphosphonates by lowering corrected serum calcium = 11. 5 mg/dL (2. 9
millimoles /L) by day 10.
Reports of Suspected Prolia (Denosumab) Side Effects
Pain in Extremity (348),
Back Pain (330),
Osteonecrosis of JAW (169),
Bone Pain (161),
Hypocalcaemia (146), more >>